Kevin Dushney

Role: Stealthco at Zenas BioPharma
Location: Ashland, MA, US
LinkedIn followers: 500 followers

ScienceView LinkedIn profile

About Kevin Dushney

I am a strategic IT leader dedicated to empowering biotechnology organizations through…

Experience

Stealthco
Zenas BioPharma
Present

Skills

Cross-Functional Team Leadership
Sharepoint
Technology Transfer
Business Analysis
Biotechnology
Change Control
Biopharmaceuticals
Lifesciences
Management
Product Development
Integration
Validation
Start-Ups
Sop
IT Strategy
Strategic Planning
Project Management
Informatics
Gmp
21 Cfr Part 11
Strategy
Saas
Life Sciences
Information Technology
Process Improvement
R&D
Pharmaceutical Industry
Vendor Management
Quality Assurance
Clinical Development
Program Management
Cloud Computing
Fda
Leadership

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@zenasbio.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Zenas BioPharma

Biotechnology Research · 198 employees · Waltham, Massachusetts, United States

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in multiple sclerosis. Zenas’ earlier stage programs include ZB021, a preclinical, potentially best-in-class, oral, IL-17AA/AF inhibitor, and ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor.

zenasbio.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Kevin Dushney

Experience

Stealthco

Skills

Find verified contacts for anyone on LinkedIn